Corrigendum: Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study (Front. Genet., (2021), 12, (699455), 10.3389/fgene.2021.699455)

In the original article, there was an error where the description of Type 2 Diabetes Miletus (T2DM) under Data Sources, Outcomes was not clear. In this study, the T2DM data “restricted to European UK Biobank participants” was used. A correction has been made to Data Sources, Outcomes: “We also included cardiovascular risk factors as secondary outcomes, including blood pressure [systolic blood pressure (SBP), diastolic blood pressure (DBP) (Mitchell et al., 2019)], body mass index (BMI) (Yengo et al., 2018), glycaemic traits [fasting glucose (FG) (Lagou et al., 2021), glycated hemoglobin (HbA1c) (Wheeler et al., 2017)], and T2DM (restricted to European UK Biobank participants) (Mahajan et al., 2018),” In addition, there were mistakes in Table 1, Supplementary Table S6, and Supplementary Figure S1 as published when describing the genetic data used for T2DM. The sample size number of T2DM (restricted to European UK Biobank participants) including case and control number was incorrect. The corrected Table 1, Supplementary Table S6, and Supplementary Figure S1 appear below. The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.